University of Ioannina
Σχεδιασμός, σύνθεση και βιολογικός έλεγχος νέων βιοδραστικών ενώσεων, αναλόγων της Νιλοτινίβης (Νilotinib) και της Ιματινίβης (Ιmatinib) ως αναστολέων πρωτεϊνικών κινασών και της πολυμεράσης της πόλυ(ΑDPριβόζης) (PARP): ανάπτυξη νέας βελτιωμένης ολικής σύνθεσης του αναστολέα Rucaparib
Abstract
dc:descriptionProtein kinase are enzymes that modifies other proteins by adding phosphate group from ATP to them, a process which is called phosphorylation. Kinases are known to mediate and regulate the majority of cellular pathways, including survival, proliferation, transcription, differentiation, apoptosis and many other cellular processes. Phosporylation of proteins results in a functional change of the target substrate of protein via the alteration of the enzyme activity. Deregulation of protein kinases lead to alterations in functions of these enzymes which may launch series of pathological diseases and cancer, including malignant disorders such aschronic myeloid leukemia, gastrointestinal stromal tumors as well as non-malignant diseases. There are indisputable evidence that protein kinases are a validated drug targets for treatment of various diseases including cancer. The tremendous appeal for development of small low-molecule weight inhibitors as a therapeutic agents against many diseases constitutes a major target by many companies. Beyond the role of protein kinases in cellular processes, a very important family of proteins are poly(ADP-ribose)polymerases, PARPs. These polymerases are enzymes that catalyze the synthesis of negatively charged and branched polymers of ADP ribose (PAR) attached to other proteins, using as a substrate NAD+. Another objective of this present Phd thesis is stated the design, synthesis, biological evaluation of a new series of analogues of Nilotinib and Imatinib, which constitute structurally related compounds to Tasigna and Gleevec with specific modifications. Besides the mentioned before modifications on the primary structrure of Nilotinib and Imatinib, another major aim of the present PhD thesis is to provide a more effective and low cost total improved synthesis for the preparation of the imatinib and nilotinib analogues, compared to the described synthetic process by Novartis. We achieved a higher overall yield and a low cost synthetic process in which all the intermediate compounds and also the final compounds were easily isolated and obtained in higher yields compared to Novartis synthetic process. Finally, the new inhibitors were purified with column chromatography, considering that it is obligatory a high purity of them in the biological tests and were fully characterized by IR, 1H-NMR, 13C-NMR spectroscopy and high resolution mass spectrometry (ESI-HRMS).
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Ntemou, Nikoleta
- Ντέμου, Νικολέτα
Subjects
dc:subject × 20- Καρκίνος
- Νιλοτινίβη
- Ιματινίβη
- Πρωτεϊνικές κινάσες
- Αναστολείς πρωτεϊνικών κινασών
- Στοχευμένη θεραπεία
- Πολυμεράση της πόλυ-(ΑDP-ριβόζη)
- Οργανική σύνθεση
- Cancer
- Nilotinib
- Imatinib
- Protein kinase
- Protein kinase inhibitors
- Targeted theraphy
- Rucaparib
- Organic synthesis
- Φυσικές Επιστήμες
- Χημεία
- Natural Sciences
- Chemical Sciences
Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/48003